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ABSTRACT Most clinical antibiotics are derived from actinomycete natural products
discovered at least 60 years ago. However, the repeated rediscovery of known com-
pounds led the pharmaceutical industry to largely discard microbial natural products
(NPs) as a source of new chemical diversity. Recent advances in genome sequencing
have revealed that these organisms have the potential to make many more NPs than
previously thought. Approaches to unlock NP biosynthesis by genetic manipulation of
strains, by the application of chemical genetics, or by microbial cocultivation have re-
sulted in the identification of new antibacterial compounds. Concomitantly, intensive ex-
ploration of coevolved ecological niches, such as insect-microbe defensive symbioses,
has revealed these to be a rich source of chemical novelty. Here, we report the new lan-
thipeptide antibiotic kyamicin, which was generated through the activation of a cryptic
biosynthetic gene cluster identified by genome mining Saccharopolyspora species found
in the obligate domatium-dwelling ant Tetraponera penzigi of the ant plant Vachellia
drepanolobium. Transcriptional activation of this silent gene cluster was achieved by ec-
topic expression of a pathway-specific activator under the control of a constitutive pro-
moter. Subsequently, a heterologous production platform was developed which enabled
the purification of kyamicin for structural characterization and bioactivity determination.
This strategy was also successful for the production of lantibiotics from other genera,
paving the way for a synthetic heterologous expression platform for the discovery of
lanthipeptides that are not detected under laboratory conditions or that are new to na-
ture.
IMPORTANCE The discovery of novel antibiotics to tackle the growing threat of antimi-
crobial resistance is impeded by difficulties in accessing the full biosynthetic potential of
microorganisms. The development of new tools to unlock the biosynthesis of cryptic
bacterial natural products will greatly increase the repertoire of natural product scaffolds.
Here, we report a strategy for the ectopic expression of pathway-specific positive regula-
tors that can be rapidly applied to activate the biosynthesis of cryptic lanthipeptide bio-
synthetic gene clusters. This allowed the discovery of a new lanthipeptide antibiotic di-
rectly from the native host and via heterologous expression.
KEYWORDS lantibiotic, lanthipeptide, plant-ant, Saccharopolyspora, cinnamycin
Antimicrobial resistance (AMR) is arguably the greatest health threat facing human-ity in the 21st century (1–3). It is predicted that without urgent action, infectious
disease will become the biggest killer of humans by 2050 (1). The majority of clinically
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used antibiotics are based on microbial natural products, isolated mostly from soil-
dwelling Streptomyces species and other filamentous actinomycete bacteria, and these
organisms remain a promising source of new antibiotics. Although the discovery
pipeline began to dry up in the 1960s, blighted by the rediscovery of known com-
pounds, we know from large-scale genome sequencing that up to 90% of microbial
natural products are not produced under laboratory conditions (4). Thus, there exists a
wealth of novel chemistry waiting to be discovered by mining the genomes of these
organisms. Bearing in mind that 600 Streptomyces species and many other so-called
“rare” actinomycetes have been described, thousands of potentially useful but “cryptic”
bioactive compounds are waiting to be discovered, even from well-characterized
strains (5, 6). Several approaches have been taken to activate cryptic pathways, includ-
ing the heterologous expression of entire biosynthetic gene clusters (BGCs) in opti-
mized Streptomyces host strains and the rewiring of BGCs to bypass their natural
regulatory mechanisms (7). The knowledge that we have barely sampled the biosyn-
thetic capabilities of known strains, and that even well-explored environments such as
soil have been undersampled for antibiotic-producing microbes, provides a much-
needed opportunity for the development of new natural product-based antibiotics.
Searching symbiotic niches for new actinomycete strains also shows great promise
for discovering new natural products (8–11). We previously described the formicamy-
cins, new polyketides with potent Gram-positive antibacterial activity produced by a
new Streptomyces species that we named Streptomyces formicae KY5 (12). This species
was isolated from a phytoecious ant species, Tetraponera penzigi, whose colonies
inhabit the African ant plant Vachellia (Acacia) drepanolobium. The ants were collected
in Kenya, hence the KY strain designation (13). These ants live in symbiosis with their
host plants, the “whistling thorn acacias,” that have evolved specialized hollow stipular
thorns called domatia to house the ants (14). In return for housing, plant ants protect
their hosts against attack by large herbivores, including elephants (15), and recent
reports have suggested that they grow specialized fungal communities inside their
domatia, possibly as a food source for their larvae (16, 17). The external cuticular
microbiome of T. penzigi ants is heterogeneous, and unbiased methods have shown
that it is dominated by members of the phyla Proteobacteria and Firmicutes, with
Actinobacteria forming a minor component (13). This contrasts with the better-studied
fungus-farming leafcutter ants of the tribe Attini, which are dominated by actinobac-
teria, specifically, by a single strain of Pseudonocardia that can be vertically transmitted
by the new queens (18, 19). Leafcutter ants feed cut plant material to their symbiotic
food fungus Leucoagaricus gongylophorus and use antifungals made by their Pseudono-
cardia symbionts to defend their food fungus against fungal parasites in the genus
Escovopsis (20–22). Despite the low abundance of Actinobacteria, we isolated several
strains, including three from the rare actinomycete genus Saccharopolyspora, which,
despite the modest number of described species, is the origin of the medically and
agriculturally important natural products erythromycin and spinosyn. Erythromycin is a
well-established clinical antibiotic that inhibits protein synthesis through binding to the
50S subunit of the ribosome (23). The spinosyns are structurally unique insecticides
used for the control of insect pests and the protection of grain products. They derive
from the fermentation of Saccharopolyspora spinosa and have potent activity and low
environmental effect (24).
Genome mining of the isolated Saccharopolyspora strains identified a conserved
BGC encoding a putative cinnamycin-like lanthipeptide antibiotic (lantibiotic) (25),
although no products for this BGC could be identified from the wild-type isolates.
Cinnamycin is a class II type B lantibiotic produced by Streptomyces cinnamoneus DSM
40005 which destabilizes the cytoplasmic membrane by binding phosphatidylethano-
lamine (PE) (25–27). Lanthipeptides belong to the ribosomally synthesized and post-
translationally modified peptide (RiPP) family of natural products (28, 29), and cinna-
mycin is the founding member of a subgroup of lanthipeptide RiPPs with antibacterial
activity that includes cinnamycin B (30), duramycin (31), duramycin B and C (32), and
mathermycin (33) (Fig. 1A). Thesemolecules are produced by actinomycetes and comprise
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19 amino acid residues, several of which are modified to generate lanthionine or methyl-
lanthionine cross-links (28, 29). Additional modifications include -hydroxylation of the
invariant aspartic acid residue at position 15 and formation of an unusual lysinoalanine
cross-link between the serine residue at position 6 and lysine residue at position 19
(34–36). The interaction of these molecules with PE has therapeutic potential: duramy-
cin binds to human lung epithelial cell membranes leading to changes in the mem-
brane or its components, promoting chloride ion secretion and clearance of mucus
from the lungs (27). On this basis, duramycin entered phase II clinical trials for the
treatment of cystic fibrosis (37).
Here, we describe activation of the cryptic Saccharopolyspora lanthipeptide BGCs
and the characterization of their product, a new class II lantibiotic that we called
kyamicin. We also exemplify a heterologous expression platform for lanthipeptide
FIG 1 Kyamicin peptide sequence and biosynthesis. (A) Alignment of core peptides of kyamicin and a selection of
known type B cinnamycin-like lantibiotics, with the positions of the thioether and lysinoalanine bridges in the
mature peptide shown. Conserved residues are highlighted in green, and similar residues are highlighted in gray.
(B) The kyamicin biosynthetic gene cluster, with genes colored according to predicted function. (C) Schematic of
kyamicin biosynthesis. The thioether bridges are formed first by dehydration of Thr4, Thr11, Thr18, and Ser6 by
KyaM to form dehydrobutyrine (Dhb) and dehydroalanine (Dha) residues, respectively. After thioether cyclization
by KyaM, Dhb becomes S-linked aminobutyric acid (Abu) and Dha becomes S-linked Ala. Asp15 is hydroxylated by
KyaX, and the lysinoalanine bridge is then formed between Dha6 and Lys19 by KyaN. After the core peptide is fully
modified, the leader peptide is proteolytically cleaved. (D) Structural representation of the mature kyamicin
lantibiotic.
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production that may be particularly useful for strains that are refractory to genetic
manipulation. The methodologies reported should be applicable for the activation of
cryptic BGCs from a wide range of actinomycetes.
(This article was submitted to an online preprint archive [38].)
RESULTS
Origin, characteristics, and genome sequencing of Saccharopolyspora strains.
The Saccharopolyspora strains were isolated from ants taken from the domatia of T.
penzigi plant ants collected in two locations in Kenya (13) and named KY3, KY7, and
KY21. The 16S rRNA gene was amplified and Sanger sequenced using universal primers
(GenBank accession numbers JX306001, JX306003, and JX306004, respectively). Align-
ments show that KY3 and KY7 are identical across the sequenced 16S rRNA gene
region, while KY21 differs by a single base pair (see Fig. S1 in the supplemental
material). Further analysis showed that all three strains share 99% sequence identity
with Saccharopolyspora 16S rRNA gene sequences in public databases. High-molecular-
weight genomic DNA was isolated from each strain, sequenced at the Earlham Institute
(Norwich, UK) using SMRT sequencing technology (Pacific Biosciences RSII platform),
and assembled using the HGAP2 pipeline as described previously (39). This gave three
circular chromosomes of approximately 6.33 Mbp, the full analysis of which will be
reported separately. Alignment of the KY3 and KY7 genome sequences using RAST
SEED Viewer and BLAST dot plot revealed a full synteny along their genomes with 99%
to 100% sequence identity at the nucleotide level, suggesting KY3 and KY7 are the
same strain and differ from KY21.
Identification of a conserved cinnamycin-like BGC. The biosynthetic potential of
all three strains was probed using the genome mining platform antiSMASH (40). The
three genomes each harbor approximately 25 BGCs with significant overlap. Among
these was a BGC for a cinnamycin-like lanthipeptide. The BGCs from strains KY3 and KY7
were identical and share 98% identity with that from KY21. They have an identical
propeptide sequence encoded by the precursor peptide gene, suggesting they all
encode the same molecule which we named kyamicin (Fig. 1B). The sequence and
annotations for these three BGCs have been deposited at GenBank under the accession
numbers MK251551 (KY3) and MK251553 (KY21).
Through comparison to the cinnamycin BGC (26) and cinnamycin biosynthesis (34),
we assigned roles to each of the genes in the kyamicin (kya) BGC (Table 1). The kya BGC
is more compact than the cinnamycin one, and the genes missing from the kyamicin
BGC are dispensable for cinnamycin production (41). The cinorf11 gene is not required
for cinnamycin production, but a homologue is present in the kyamicin cluster. While
cinorf11 lacks a plausible stop codon and its reading frame extends 570 bp into the
cinR1 gene, its homologue, kyaorf11, has a stop codon and does not run into the kyaR1
gene, suggesting it may encode a functional protein.
TABLE 1 Proteins encoded by the kyamicin, cinnamycin, and duramycin BGCs
Kyamicin BGC (no. of aa) Cinnamycin BGC (no. of aa) Duramycin BGC (no. of aa) Proposed function
KyaN (123) CinN (119) DurN (119) Formation of lysinoalanine bridge
KyaA (78) CinA (78) DurA (77) Precursor peptide
KyaM (1,065) CinM (1,088) DurM (1,083) Formation of lanthionine residues
KyaX (302) CinX (325) DurX (327) Hydroxylation of Asp15
KyaT (327) CinT (309) DurT (352) Export
KyaH (294) CinH (290) DurH (290) Export
Not present CinY DurY Not essential
Not present CinZ DurZ Not essential
Not present Cinorf8 Durorf8 Not essential
Not present Cinorf9 Not present Not essential
KyaR (216) CinR (216) DurR (216) Regulation
KyaK (372) CinK (354) DurK (349) Regulation
KyaL (226) CinL (236) DurL (235) Immunity
Kyaorf11 (295) Cinorf11 (396) Durorf11 (396) Not essential
KyaR1 (260) CinR1 (261) DurR1 (261) Regulation
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To detect production of kyamicin, we grew all three strains on a range of 13 liquid
media (see Table S1) and collected extracts after 4, 5, 6, and 7 days of growth by using
(individually) methanol and ethyl acetate. Analysis of the extracts using ultraperfor-
mance liquid chromatography-mass spectrometry (UPLC-MS) failed to identify the
anticipated product (the methods were validated using authentic duramycin). This was
consistent with parallel bioassays which failed to show any antibacterial activity for the
extracts against Bacillus subtilis EC1524, which is sensitive to cinnamycin (26). Similarly,
no activity was observed in overlay bioassays.
Activation of the kyamicin BGC. Cinnamycin production and immunity ultimately
rely on two gene products (41). The transcription of the biosynthetic genes is driven by
CinR1, one of the Streptomyces antibiotic regulatory proteins (SARP) (which usually act
as pathway-specific transcription activators), and immunity is conferred by a methyl-
transferase (CinL) that modifies PE in the membrane to prevent binding of cinnamycin.
We reasoned that transcription of the homologues of these two genes (kyaR1 and kyaL,
respectively), driven by a constitutive promoter, would circumvent the natural regula-
tory mechanism and initiate production of kyamicin. To achieve this, we made a
synthetic construct, pEVK1, containing kyaR1-kyaL (in that order) (see Fig. S2A). The
kyaR1-kyaL cassette was cloned into pGP9 (42) to yield pEVK4, which was introduced
into the three Saccharopolyspora strains by conjugation. This resulted in single copies
of the plasmid integrated at the BT1 phage integration site of each strain. Exconju-
gants were assayed by overlaying with B. subtilis EC1524, revealing zones of clearing for
all three strains containing pEVK4 (Fig. 2A; see also Fig. S3). For the KY21 exconjugant,
agar plugs were taken from the zone of clearing, extracted with 5% formic acid, and
analyzed by UPLC-MS (Fig. 2A). In contrast to the relevant controls, an ion atm/z 899.36
was observed corresponding to the expected [M 2H]2 ion of kyamicin (Table 2).
Heterologous expression of the kyamicin BGC. Attempts to scale up cultures of
Saccharopolyspora sp. KY21/pEVK4 to generate sufficient material for further study were
not successful due to low titers and poor growth of the strain. Consequently, we
attempted heterologous expression of the kya BGC in the well-established host Strep-
tomyces coelicolor M1152 (43). To achieve this, we cloned kyaR1L as an NdeI/HindIII
fragment into pIJ10257 (44); this yielded pEVK6, which has the constitutive ermE*
promoter driving expression of kyaR1L. We then commissioned a synthetic operon
containing the regions harboring kyaN to kyaH plus the upstream promoter region of
kyaN as an EcoRI/XbaI fragment (Fig. S2B). This was cloned into pSET152 (45) to give
pWDW63, which integrates into the S. coelicolor chromosome at the C31 integration
site, conferring apramycin resistance. pEVK6 and pWDW63 were then introduced
sequentially into S. coelicolor M1152 via conjugation, and apramycin- plus hygromycin-
resistant exconjugants were grown on R5 agar and overlaid with B. subtilis EC1524. In
contrast to the control strains, these gave a pronounced zone of clearing. Agar plugs
were taken from the zone of clearing, extracted, and analyzed by UPLC-MS, revealing
the expected [M 2H]2 ion for kyamicin which was not present in the controls (Fig.
2B). In addition to kyamicin, a second minor new compound was observed with an m/z
value of 891.36, consistent with the production of a small amount of deoxykyamicin,
presumably reflecting incomplete -hydroxylation of the aspartic acid residue at
position 15 (Table 2 and Fig. S4).
Having established the production of kyamicin in the M1152 heterologous host, we
used this system to better understand how each gene product contributes to the
activation of kyamicin biosynthesis. We cloned kyaL and kyaR1 separately into pIJ10257
to give pEVK12 and pEVK13, respectively. Each plasmid was then introduced into
M1152 alongside pWDW63, and doubly antibiotic-resistant exconjugants were se-
lected. These were grown on R5 agar plates and overlaid with B. subtilis EC1524; agar
plugs were extracted from the resulting bioassay plates as before. For M1152/pEVK12
(kyaL only) no growth inhibition of the bioassay strain was observed and we could not
detect kyamicin or deoxykyamicin using UPLC-MS. For M1152/pEVK13 (kyaR1 only), we
observed a zone of inhibition which was approximately three times smaller than for the
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M1152/pEVK6 (kyaR1L) positive control. UPLC-MS analysis of the M1152/pEVK13 strain
detected only deoxykyamicin (Fig. S4). No significant change in overall titers was
observed between these strains, and we ruled out the possibility of suppresser muta-
tions in kyaX (encoding the hydroxylase) by PCR amplification and sequencing of the
DNA encoding this gene and the surrounding region (data not shown). This is consis-
tent with previous work which reported that deoxy versions of lantibiotics have lower
biological activity (46).
Isolation, structure elucidation, and bioactivity. To isolate and verify the struc-
ture of kyamicin, growth of S. coelicolor M1152/pEVK6/pWDW63 was scaled up in liquid
culture, and the cell pellet was extracted with 50% methanol. Crude extracts were
FIG 2 Activation of kyamicin biosynthesis and heterologous expression. Overlay bioassays were carried out with B.
subtilis EC1524, and agar plugs were taken adjacent to the central streak and analyzed by UPLC-MS. Extracted ion
chromatograms are shown for m/z 899.36 ([M 2H]2). Images and LC traces are representative of at least three
biological repeats. (A) Activation of kyamicin production in KY21 strains. The pEVK4 vector containing kyaR1 and
kyaL results in a zone of inhibition, corresponding to the production of kyamicin, in contrast to the pGP9 empty
vector control or the wild-type strain. (B) Heterologous expression of kyamicin in S. coelicolor M1152. A zone of
inhibition, corresponding to kyamicin production, is observed only when pWDW63 carrying the kya biosynthetic
genes is expressed in combination with pEVK6 carrying kyaR1 and kyaL.




Kyamicin C76H108N20O25S3 899.3551 899.3553 0.22
Deoxykyamicin C76H108N20O24S3 891.3576 891.3557 2.13
Partially reduced kyamicin C76H110N20O25S2 884.3768 884.3767 0.11
Partially reduced kyamicin C76H112N20O25S 869.3987 869.3990 0.35
Reduced kyamicin C76H114N20O25 854.4204 854.4202 0.23
Duramycin C89H125N23O25S3 1,006.9262 1,006.9232 2.98
Deoxyduramycin C89H125N23O24S3 998.9287 998.9253 3.40
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further purified using semipreparative high-performance liquid chromatography
(HPLC) to yield pure kyamicin (2.5 mg).
As the methyllanthionine bridges of kyamicin limit the ability to induce fragmen-
tation in tandem mass spectrometry (MS/MS) experiments, the lantibiotic was sub-
jected to chemical reduction with NaBH4-NiCl2 using a procedure published previously
for the related molecule cinnamycin B (30). This leads to removal of the methyllan-
thionine bridges, and as anticipated, UPLC-MS of the product molecule showed an
[M 2H]2 ion at m/z 854.42 corresponding to the loss of three sulfur atoms and gain
of six hydrogen atoms (Table 2 and Fig. 3). Tandem MS experiments were carried out
using both electrospray ionization (ESI) and matrix-assisted laser desorption ionization–
time of flight (MALDI-TOF) methods. While ESI gave a complex mixture of fragmenta-
tion ions, for MALDI-TOF, the y ion (NH3) series could be clearly observed, with
fragmentation at the lysinoalanine bridge appearing to occur via a rearrangement to
give a glycine residue at position 6 and NCH2 at the end of the lysine side chain (see
Fig. S5). The connectivity of the peptide was consistent with the primary sequence of
kyamicin predicted by our bioinformatics analysis.
The chemical structure was further examined by nuclear magnetic resonance (NMR)
experiments comprising 1H, heteronuclear single quantum coherence (HSQC) spectros-
copy, total correlation spectroscopy (TOCSY), and nuclear Overhauser effect spectros-
copy (NOESY) analyses. Overall, 14 spin systems were partially or completely identified
in the TOCSY spectrum. These were putatively assigned based on their spatial relation-
ship determined from the NOESY spectrum. Coupling in the HSQC spectrum then
allowed identification of several C atoms in the molecule. Spectra and assignments can
be found in Fig. S6 and Table S2.
FIG 3 Characterization of kyamicin. The connectivity of the peptide was confirmed by chemical reduction followed by tandem MS fragmentation. Reduction
with NaBH4-NiCl2 resulted in the cleavage of the methyllanthionine bridges (blue), corresponding to the loss of three S atoms and gain of six H atoms, with
a mass shift from m/z 899.36 ([M 2H]2) to m/z 854.42 ([M 2H]2). Tandem MS using the MALDI-TOF LIFT method allowed identification of the y ion (NH3)
series for the complete peptide (see Fig. S5 in the supplemental material). Fragmentation of the lysinoalanine bridge (pink) occurred via rearrangement to give
NCH2 at the terminus of the lysine side chain and a glycine residue at position 6.
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The bioactivity of the purified compound was compared with cinnamycin and
duramycin using the spot-on-lawn method. The MIC of kyamicin against B. subtilis
EC1524 was 128 g/ml, whereas duramycin inhibited at 32 g/ml and cinnamycin at
16 g/ml, representing 4- and 8-fold MIC increases, respectively (Fig. 4).
Cross-species activation of the duramycin BGC. Many cinnamycin-like BGCs can
be identified in the published sequence databases, but their products remain cryptic.
Thus, the potential of the kyaR1-kyaL construct to induce expression of other
cinnamycin-like lantibiotics was explored.
The BGC for duramycin was cloned previously from Streptomyces cinnamoneus ATCC
12686 (Fig. 5A), but attempts to produce the lantibiotic heterologously failed. Conse-
quently, the duramycin BGC was reconfigured in pOJKKH, which contains all the
biosynthetic genes but lacks immunity and regulatory genes and has a SARP binding
site upstream of durN that is similar to that upstream of kyaN (Fig. 5B) (41). pOJKKH and
FIG 4 Comparative bioassay of kyamicin, duramycin, and cinnamycin against B. subtilis EC1524. The MIC
of each substance was determined by direct application of serial dilutions of the compounds in water on
a SNA plate inoculated with B. subtilis EC1524. NC, H2O (negative control). Kyamicin displays an MIC of
128 g/ml, whereas duramycin inhibits at 32 g/ml and cinnamycin at 16 g/ml.
FIG 5 Schematic of duramycin BGC and plasmids used to construct pOJKKH, and SARP binding sites of kyamicin, cinnamycin,
and duramycin. (A) The S. cinnamoneus DNA sequences represented on the plasmids pDWCC2 and pDWCC3 are present in the
published genome sequence as bp 81593 to 99144 of contig NZ_MOEP01000024.1. pDWCC2 consists of the area from the left
KpnI site (from durorf1) to the central KpnI site in durX. pDWCC3 consists of the area covering from the central KpnI site in durX
to the right-side KpnI site after a putative integrase-encoding gene. The putative duramycin resistance/regulatory genes are
represented in the published genome sequence by bp 54637 to 59121 of contig NZ_MOEP01000113.1. (B) Sequence alignment
of putative SARP binding sites of kyamicin, cinnamycin, and duramycin. Conserved residues within all three sequences are
marked with asterisks, and the 5-bp SARP binding motifs are in bold font. The alignment was performed with Clustal Omega
(v1.2.4).
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pEVK6 were introduced sequentially into S. coelicolor M1152 via conjugation and the
resulting exconjugants assessed for duramycin production. Overlay bioassays using B.
subtilis EC1524 indicated the production of an antibacterial molecule by S. coelicolor
M1152/pOJKKH/pEVK6 (Fig. 6). Agar within the growth inhibition zone was extracted
and the resulting sample analyzed by UPLC-MS. An ion at m/z 1,006.92 was observed,
corresponding to the expected [M 2H]2 ion for duramycin (Table 2). The production
of duramycin was confirmed by comparison to an authentic standard. A deoxy deriv-
ative was also detected with an m/z of 998.93 (Table 2), typically at 30% the level of
duramycin. Expression of pOJKKH alone or in conjunction with the empty pIJ10257
vector did not result in duramycin biosynthesis, demonstrating that expression of both
kyaR1 and kyaL is required to induce heterologous duramycin biosynthesis in S.
coelicolor M1152. Thus, we have shown that the SARP and immunity genes from a
cinnamycin-like BGC from a Saccharopolyspora species can be used to activate a
cinnamycin-like BGC from a Streptomyces species, a cross-genus activation.
DISCUSSION
Three isolates from the rare actinomycete genus Saccharopolyspora were isolated
from the external microbiome of T. penzigi plant ants collected at two locations in
Kenya more than 50 km apart (13). Despite this geographical separation, their genomes
were extremely similar, and analysis using antiSMASH identified almost identical bio-
synthetic capabilities. Among the conserved BGCs was one encoding a cinnamycin-like
lantibiotic, which we named kyamicin.
Despite culturing on a wide range of media, we were unable to elicit production of
kyamicin in the wild-type Saccharopolyspora strains. The production of cinnamycin in S.
cinnamoneus DSM 40005 requires the expression of two key genes, cinR1 and cinL,
encoding a pathway-specific regulatory protein (a SARP) and an immunity protein (a PE
methyltransferase), respectively (41). As the kya BGC contains homologues of these
genes, we expressed them constitutively in the three Saccharopolyspora strains, which
led to activation of the BGC and production of kyamicin. Since we were unable to
isolate enough kyamicin from these strains for further study, a heterologous production
platform was developed using S. coelicolor M1152, which allowed us to confirm the
structure of kyamicin and assess its antibacterial activity. The chemical structure of
kyamicin differs from that of cinnamycin and duramycin at 6 of the 19 amino acid
residues but not at any involved in formation of the lanthionine or lysinoalanine
bridges.
Having demonstrated the utility of a constitutively expressed SARP/immunity cas-
sette for driving expression of the otherwise silent kya BGC, we utilized this knowledge
FIG 6 Activation of duramycin biosynthesis. Overlay bioassays were carried out with B. subtilis EC1524,
and agar plugs were taken adjacent to the central streak and analyzed by UPLC-MS. Extracted ion
chromatograms are shown for m/z 1,006.93 ([M 2H]2). Duramycin was only detected in the strain
carrying both pOJKKH and pEVK6. The duramycin peak aligns with an authentic standard of duramycin
(0.1 mg/ml in 5% formic acid), shown on a separate scale. Images and LC traces are representative of at
least three biological repeats.
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to activate duramycin production in a heterologous host. Contemporaneous with our
experiments, the duramycin BGC was also identified by genome sequencing of S.
cinnamoneus ATCC 12686 (35). This analysis described the same genomic region
containing durN to durH and surrounding genes (Table 1) but failed to reveal putative
regulatory and immunity genes. Coexpression of durA, durM, durN, and durX in Esche-
richia coli was sufficient to direct the biosynthesis of duramycin A, and the functions of
DurA, DurM, DurN, and DurX were confirmed by detailed biochemical analyses. Our
subsequent bioinformatic analysis of the published genome sequence identified ho-
mologs of the immunity genes cinL and kyaL and the regulatory genes cinRKR1 and
kyaRKR1 in the region from bp 54637 to 59121 of contig MOEP01000113.1 from the
deposited genome sequence (accession no. NZ_MOEP00000000). This region is sepa-
rated from the dur biosynthetic genes by a section of DNA with low GC content, the
analysis of which suggests that a phage or other mobile element may have inserted
between durZ and durorf8 (Fig. 5). Thus, it appears likely that the immunity and
regulatory mechanisms described previously for the control of cinnamycin biosynthesis
are conserved for duramycin biosynthesis in S. cinnamoneus ATCC 12686.
Given the potential utility of cinnamycin-like class II lanthipeptides in several
therapeutic contexts, the ability to generate analogues of these compounds with
modified properties and in sufficient quantity for preclinical assessment is of significant
value. The methods described here provide a platform for the identification of addi-
tional natural lanthipeptides whose biosynthesis cannot be detected in the host strain
and for the diversification of their chemical structures to generate new-to-nature
molecules.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. All bacterial strains and plasmids used in this
study are listed in Table 3. Saccharopolyspora and Streptomyces strains were grown on soya flour-
mannitol (SFM) agar medium with appropriate antibiotics at 30°C unless otherwise stated. E. coli and B.
subtilis EC1524 strains were grown on lysogeny broth (LB) medium with appropriate antibiotics at 37°C.
R5 agar (47) was used for bioassay plates.
DNA extraction and genomic analysis. The salting-out method (47) was used to extract genomic
DNA. The DNA was sequenced at the Earlham Institute (Norwich, UK) using SMRT sequencing technology
(Pacific Biosciences RSII platform) and assembled using the HGAP2 pipeline (39).
Overlay bioassays. For each strain to be tested, a streak from a spore stock was applied in the center
of an R5 agar plate and left to grow for 7 days. B. subtilis EC1524 was grown from a single colony
overnight and then diluted 1:20 in fresh medium and grown until an optical density at 600 nm (OD600)
of 0.4 to 0.6. The exponential culture was mixed with 1:100 molten soft nutrient agar (SNA) (47), and the
mixture was used to overlay the plate (5 ml SNA mixture/agar plate). The plate was incubated at room
temperature overnight.
Extractions from overlay bioassays. Plugs of agar 6.35 mm in diameter were taken adjacent to the
streaked actinomycete strain on an overlay bioassay plate, corresponding to the zone of growth
inhibition where one was observed. Agar plugs were frozen at 80°C for 10 min and thawed, and then
300 l of 5% formic acid was added. This was vortexed briefly and shaken for 20 min. After centrifugation
(15,682  g for 15 min), the supernatant was collected and filtered using a filter vial (HSTL Labs) prior to
UPLC-MS analysis.
UPLC-MS. Data were acquired with an Acquity UPLC system (Waters) equipped with an Acquity UPLC
BEH C18 column, 1.7 m, 1 mm by 100 mm (Waters), connected to a Synapt G2-Si high-resolution mass
spectrometer (Waters). For analytical UPLC, 5.0 l of each sample was injected and eluted with mobile
phases A (water-0.1% formic acid) and B (acetonitrile-0.1% formic acid) at a flow rate of 80 l/min. Initial
conditions were 1% B for 1.0 min, ramped to 40% B within 9.0 min, ramped to 99% B within 1.0 min, held
for 2 min, returned to 1% B within 0.1 min, and held for 4.9 min.
MS spectra were acquired with a scan time of 1.0 s in the range of m/z 50 to 2,000 in positive-
resolution mode. The following parameters were used: capillary voltage, 3.0 kV; cone voltage, 40 V;
source offset, 80 V; source temperature, 130°C; desolvation temperature, 350°C; desolvation gas flow,
700 liters/h. A solution of sodium formate was used for calibration. Leucine encephalin peptide (H2O-
methanol [MeOH]-formic acid [49.95:49.95:0.1]) was used as lock mass (556.2766m/z) and was injected
every 30 s during each run. The lock mass correction was applied during data analysis.
Design of kya BGC activation and immunity plasmids. pEVK1, a pUC57 derivative, contains the
synthetic kyaR1 and kyaL (GenScript) arranged as an operon. pEVK1 has an NdeI site overlapping the start
codon of kyaR1 and a HindIII site immediately after the stop codon of kyaL, with the two genes separated
by a short intergenic region containing a ribosome binding site (RBS) designed from the RBS of cinN
(chosen because its sequence is most similar in the BGC to that of an ideal RBS) (see Fig. S2A in the
supplemental material). The NdeI-HindIII kyaR1L fragment from pEVK1 was cloned into pGP9 (42) to give
pEVK4, and into pIJ10257, a BT1-based integrative expression vector with a hygromycin resistance
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marker (44), to give pEVK6. kyaR1 and kyaL were amplified individually as NdeI-HindIII-compatible
fragments using the primers AmplkyaR1-F (GCGCAAGCTTCTACGACGCGGTGTGA) and AmplkyaR1-R (GC
GCGCCATATGAAACCGCTGTCGTTCC) for kyaR1, and AmplkyaL-F (GCGCGCCATATGGATCCAGTACAGA
CCA) and AmplkyaL-R (GCGCAAGCTTTCAGCGGTCCTCCGCC) for kyaL; they were cloned as NdeI-HindIII
fragments into pIJ10257 to yield pEVK12 and pEVK13, respectively. PCR-generated fragments were
verified by Sanger sequencing.
Cloning the duramycin BGC from Streptomyces cinnamoneus ATCC 12686. The cloning of an
5-kb BglII fragment of chromosomal DNA to create pIJ10100 was described previously (26). This
plasmid has a KpnI site in the middle of durX. KpnI fragments upstream and downstream of this KpnI site
were identified by Southern blotting and isolated by creating a minilibrary of KpnI fragments in
pBluescriptIIKS followed by colony hybridization to give pDWCC2 and pDWCC3, respectively. Analysis of
the sequence of these plasmids identified 15 genes (shown in Fig. 5). A plasmid carrying the duramycin
biosynthetic genes but not the putative phage DNA was prepared by digesting pDWCC3 with XhoI and
HindIII (site is in the multiple cloning site of pBluescript II KS) removing the 5= end of durZ and the
putative phage DNA. This region was replaced with a XhoI- and HindIII-cut PCR fragment that reconsti-
tuted the portion of durZ removed in the previous step and introduced a HindIII site upstream of the durZ
start codon. The 666-bp PCR fragment was generated using the primers BK10 (GAGCTTGACGCCGCCG
AAGTAGC) and Hindprim (GCGGCGAAGCTTGAGGTGGCCTCCTCCACGAAGCCA) with pDWCC3 as the
template and was cut with XhoI plus HindIII to give a 363-bp fragment. The resulting plasmid was then
TABLE 3 Strains and plasmids used in this work





KY3 Strain from the cuticles of Tetraponera penzigi This work
KY3/pGP9 KY3 strain carrying the empty pGP9 plasmid This work
KY3/pEVK4 KY3 strain carrying pEVK4, which activates kyamicin production This work
KY7 Strain from the cuticles of Tetraponera penzigi This work
KY7/pGP9 KY7 strain carrying the empty pGP9 plasmid This work
KY7/pEVK4 KY7 strain carrying pEVK4, which activates kyamicin production This work
KY21 Strain from the cuticles of Tetraponera penzigi This work
KY21/pGP9 KY21 strain carrying the empty pGP9 plasmid This work
KY21/pEVK4 KY21 strain carrying pEVK4, which activates kyamicin
production
This work
Streptomyces coelicolor Non-antibiotic-producing superhost, Δact Δred Δcpk Δcda
rpoB(C1298T)
43
M1152/pEVK6 M1152 carrying pEVK6 This work
M1152/pWDW63 M1152 carrying the kyamicin biosynthetic genes This work
M1152/pEVK6/pWDW63 M1152 carrying the kyamicin biosynthetic genes and pEVK6,
which activates kyamicin production
This work
M1152/pWDW63/pEVK12 M1152 carrying the kyamicin biosynthetic genes pEVK12 for
constitutive expression of kyaL
This work
M1152/pWDW63/pEVK13 M1152 carrying the kyamicin biosynthetic genes pEVK13 for
constitutive expression of kyaR1
This work
M1152/pOJKKH M1152 carrying the duramycin biosynthetic genes This work
M1152/pEVK6/pOJKKH M1152 carrying the duramycin biosynthetic genes and pEVK6,
which activates duramycin production
This work
Bacillus subtilis EC1524 Bioassay strain; trpC2, subtilin BGC deleted 26
Plasmids
pGP9 pSET152-derived BT-based integrative expression vector 42
pIJ10257 oriT, BT1 attB-int, Hygr, ermEp* 44
pSET152 C31 attP-conjugative vector 45
pEVK1 pUC57/R1L Synthetic construct with kyaR1L genes GenScript
pEVK4 pGP9/R1L for constitutive expression of kyaR1L in
Saccharopolyspora
This work
pEVK6 pIJ10257/R1L for constitutive expression of kyaR1L in S.
coelicolor
This work
pEVK12 pIJ10257/L for constitutive expression of kyaL in S. coelicolor This work
pEVK13 pIJ10257/R1 for constitutive expression of kyaR1 in S. coelicolor This work
pWDW60 pUC57/Kya synthetic construct with the kyamicin biosynthetic
genes kyaN to kyaH
GenScript
pWDW63 pSET152/Kya for constitutive expression of the kyamicin
biosynthetic genes in S. coelicolor
This work
pOJKKH pOJ436-based plasmid carrying the duramycin biosynthetic
genes durN to durZ
This work
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digested with KpnI plus XbaI (the XbaI site is in the multiple cloning site of pBluescript II KS), and the
fragment carrying putative duramycin genes was cloned into KpnI-plus-XbaI-cleaved pOJ436 to give
pOJKH. The KpnI fragment from pDWCC2 was then cloned into pOJKH cut with KpnI to give pOJKKH,
which was verified by BglII digestion, thus restoring the original gene context.
Isolation and purification of kyamicin. S. coelicolor M1152/pWDW63/pEVK6 was grown in tryptic
soy broth (12 2.5-liter Erlenmeyer flasks, each containing 500 ml) and incubated at 28°C and 200 rpm on
an orbital shaker for 7 days. The cells were harvested and extracted with methanol-water (1:1,500 ml)
with ultrasonication for 2 h and subsequent shaking for 16 h. After centrifugation, the supernatant was
filtered and concentrated under vacuum, giving 613 mg of crude material, which was then purified by
semipreparative HPLC. Chromatography was achieved over a Phenomenex Gemini-NX reversed-phase
column (C18, 110 Å, 150 mm by 21.2 mm) using a Thermo Scientific Dionex UltiMate 3000 HPLC system.
A gradient was used with mobile phases A (H2O with 0.1% formic acid) and B (methanol): 0 to 1 min, 10%
B; 1 to 35 min, 10% to 85% B; 35 to 40 min, 85% to 100% B; 40 to 45 min, 100% B; 45 to 45.1 min, 100%
to 10% B; 45.1 to 50 min, 10% B; flow rate, 20 ml/min; injection volume, 1,000 l. Absorbance was
monitored at 215 nm, and fractions (20 ml) were collected and analyzed by UPLC-MS. Kyamicin was
observed in fractions 22 to 25, which were combined and concentrated to yield an off-white solid
(2.5 mg).
MIC determination. The spot-on-lawn method was used to determine lantibiotic MICs. A 1,000-
g/ml stock solution of each lantibiotic was prepared using sterile water, along with serial dilutions from
256 to 8 g/ml. B. subtilis EC1524 was grown and mixed with molten SNA as described above to create
a lawn of bacterial growth. Once set, 5 l of each dilution was applied directly to the agar and incubated
overnight at room temperature. The MIC was defined as the lowest concentration for which a clear zone
of inhibition was observed.
Chemical reduction of kyamicin. Kyamicin (1 mg) was dissolved in methanol (0.5 ml) and added to
an aqueous solution of NiCl2 (20 mg/ml; 0.5 ml). The solution was mixed with solid NaBH4 (5 mg),
resulting in the generation of hydrogen gas and the formation of a black Ni2B precipitate. The tube was
immediately sealed, and the mixture was stirred at 55°C. The reaction progress was monitored by
UPLC-MS as described above, for which a peak with an m/z of 899.36 was observed for kyamicin
([M 2H]2). The successive formation of peaks with the following masses was observed: m/z 884.38,
869.40, and 854.42, corresponding to the successive reduction of the three thioether bridges. After 5 h,
only the ion with m/z 854.42 was observed, indicating that the starting material had been completely
reduced. The precipitate was collected by centrifugation at 15,682  g for 10 min. As the reaction
supernatant contained only trace amounts of the desired product, a fresh solution of MeOH-H2O (1:1;
0.5 ml) was added to the precipitate and it was subjected to ultrasonication for 30 min. Reduced kyamicin
was then detected in sufficient quantity for MS/MS experiments to confirm the peptide sequence.
MS analysis of reduced kyamicin. For ESI-MS/MS analysis, the mass of interest (854.42) was selected
using an inclusion list and fragmented using data-directed analysis (DDA) with the following parameters:
top3 precursor selection (inclusion list only); MS2 threshold, 50,000; scan time, 0.5 s without dynamic
exclusion. Collision energy (CE) was ramped between 15 and 20 at low mass (50m/z) and 40 to 100 at
high mass (2,000m/z). Further increase of the CE from 20 to 30 and from 60 to 120 led to complete
fragmentation.
For MALDI-TOF-MS, the samples were mixed with -cyano-4-hydroxycinnamic acid as matrix and
analyzed on an Autoflex Speed MALDI-TOF/TOF mass spectrometer (Bruker Daltonics GmbH). The
instrument was controlled by a flexControl (version 3.4; Bruker) method optimized for peptide detection
and calibrated using peptide standards (Bruker). For sequence analysis, fragments produced by post-
source decay (PSD) were measured using the LIFT method (Bruker). All spectra were processed in
flexAnalysis (version 3.4; Bruker).
NMR experiments. NMR measurements were performed on a Bruker Avance III 800-MHz spectrom-
eter. Chemical shifts are reported in parts per million (ppm) relative to the solvent residual peak of
DMSO-d6 (1H: 2.50 ppm, quintet; 13C: 39.52 ppm, septet).
Data availability. The sequence and annotations for these three BGCs have been deposited at
GenBank under the accession numbers MK251551 (KY3) and MK251553 (KY21).
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
SUPPLEMENTAL FILE 1, PDF file, 0.8 MB.
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